germany-erfurt: pharmaceutical products./ conclusion of non-exclusive drug discount agreements according to § 130a para. 8 sgb v by means of a so-called open house model for the active ingredient eslicarbazepine (atc code according to who: n03af04)./ the subject of this publication is the conclusion of non-exclusive discount agreements in accordance with section 130a (8) sgb v for medicinal products containing the active substance eslicarbazepine (atc code according to who: n03af04). the contract is concluded as part of a so-called open-house model, i. h. a contract is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. as a result, individual contract negotiations are not conducted and (delivery) exclusivity does not exist. it is pointed out that the purchase quantity is unknown, since this depends on the demand and the development of the number of insured persons, on the preion behavior of the doctors as well as the dispensing and stocking behavior of the public pharmacies. accordingly, minimum purchase quantities are not guaranteed. for more information, please refer to point ii.2.4) of the announcement.